

27th April, 2009

PHARMACY CHAIN 36,6 ANNOUNCES Q1 2009 TRADE UPDATE (UNAUDITED)

April 27, 2009, MOSCOW – OJSC Pharmacy Chain 36.6 [RTS:APTK; MICEX:RU14APTK1007] the leading Russian pharmaceutical retailer announces unaudited sales and operational results according to the management accounts.

GROUP SALES¹:

- Y-O-Y Group's consolidated sales decreased by 38.8% and reached USD 171.5 million.
- Y-O-Y Pharmacy Retail Sales decreased by 38.9% in dollar terms and reached USD 140.3 million versus 229.6 in Q1 2008 (in ruble terms retail sales decreased by 13.2% from 5 496.1 mln RUB in Q1 2008 to 4 769.5 mln RUB in Q1 2009).
- Y-O-Y Sales of finished goods of the production unit Veropharm decreased by 22.0% and reached USD 26.1 million.
- Y-O-Y other non-core businesses decreased by 67.5% as the Company no longer consolidates the operation of European Medical Center.

<i>USD mln</i>	Consolidated	Retail	Veropharm	Other
Q1 2009	171.5	140.3	26.1²	5.1
Q1 2008	280.0	229.6	34.7³	15.7
<i>Change y-o-y</i>	<i>-38.8%</i>	<i>-38.9%</i>	<i>-22.0%</i>	<i>-67.5%</i>

Jere Calmes, President and CEO of Pharmacy Chain 36.6:

"Our first quarter sales numbers are representative of the considerable decline of the ruble dollar exchange rate and the extraordinary pressures of the global economic crises that translates for us into a challenging operating environment and difficulty in finding sources of funding. The regions of Russia have been more severely affected than our core Moscow market and management continues to focus on rigorously attacking operating expenses, closing non-performing stores and delivering low cost, high quality products to our clients."

RETAIL:

- As of the end of Q1 2009 Pharmacy Chain 36.6 operated 1084 stores in 29 regions of Russia.
- During Q1 2009 7 stores were opened organically and 50 were closed (no stores were rebranded or reformatted).
- As of the end of Q1 2009 Pharmacy Chain 36.6 operated 9 ELC stores, 14 stand-alone optical outlets and 19 additional optical departments within pharmacies.

¹ Hereinafter – these financial indicators may vary from the consolidated financial reporting prepared in accordance with IFRS.

² Sales of Veropharm's finished goods

³ Sales of Veropharm's finished goods – USD 33.3 mln, other revenue – USD 1.4 mln.

As of 31.03.2009

Business Unit	No. of pharmacies	Share of Sales	Ave. retail space per pharmacy, sq.m.
1. Moscow-Central	364	45.4%	75.4
<i>Northwest</i>	<i>25</i>	<i>2.73%</i>	<i>68.3</i>
2. South Urals	248	17.5%	57.1
3. South	189	16.0%	51.2
4. Volga	127	9.3%	61.4
5. North Urals	94	7.2%	53.4
6. Siberia	62	4.6%	53.1
Company Total:	1084	100%	62.2

OPERATIONAL DATA FOR THE RETAIL UNIT:

- During Q1 2009 21.0 million purchases were made in Pharmacy Chain 36.6, which is 23.5% lower than in Q1 2008.
- In Q1 2009 average check across the network reached USD 6.92 (RUR 235), in Moscow - USD 9.8 (RUR 332), a decrease over 15.8% and 16.2% respectively in dollar terms and a growth of 18.1% and 17.3% respectively in ruble terms.
- Average sales floor size in Q1 2009 is 62.2 sq meters, an increase of 1.6% versus Q1 2008.

PRIVATE LABEL:

- In Q1 2009 the private label sales reached USD 8.3 mln (RUR 279.6 mln) which represents a 44.4% growth in dollar terms and 103.9% growth in ruble terms compared to Q1 2008.
- In Q1 2009 the share of private label sales reached 6%.
- The number of SKUs has increased by 73.3% from 427 at the end of Q1 2008 to 740 by the end of Q1 2009.

LIKE-FOR-LIKE SALES IN COMPARABLE STORES⁴:

As of the end of Q1 2009 the Company operates 619 comparable stores representing 66 % of sales and 62% of traffic in the retail unit in Q1 2009.

L-F-L sales reduction in these stores reached 35% as compared to Q1 2008 (in dollar terms) and 8% decrease (in ruble terms) while traffic decreased by 21%:

Business unit	Number of comparable stores	L-F-L sales growth USD	L-F-L sales growth RUR	Average check growth, USD	Average check growth, RUR
1.Moscow-Central	224	-30%	-1%	-16%	17%
<i>Northwest</i>	<i>21</i>	<i>-29%</i>	<i>-1%</i>	<i>-18%</i>	<i>15%</i>
2.South Urals	175	-40%	-15%	-20%	12%
3.South	82	-39%	-14%	-19%	14%
4.Volga	87	-37%	-12%	-19%	13%
5.North Urals	37	-43%	-20%	-21%	11%
6.Siberia	14	-32%	-5%	-14%	20%
Total:	619	-35%	-8%	-17%	17%

⁴ Comparable stores are defined as stores:

- Opened or acquired 24 months from the current reporting period, and
- Neither rebranded nor reformatted or significantly changed during the last 24 months, and
- Not closed in the current reporting period.

DEBT:

As of the end of Q1 2009, the total Group's financial debt (the principal amount) declined to USD 141.2 million from USD 150.5 by the end of 2008 due to exchange rate effect.

#

For further information please refer to:

Svetlana Belkina

PR Manager

OJSC «Pharmacy Chain 36,6»

belkina@OAO366.ru

tel. (+7 495) 797 86 81

ext.17-04

Natalia Kharchevnikova

IR Manager

Management company «Pharmacy Chain 36,6»

kharchevnikova.n.g@366.ru

tel. (+7 495) 797 86 81

ext.17-63

Or to the web-site of the company:

www.pharmacychain366.ru

ir@oao366.ru

Notes to the editor:

Pharmacy Chain 36.6 is the first public national health and beauty retailer listed on the "B" list on the RTS (ticker: APTK) and off-list on the MICEX. The Company's market capitalization as of April 24, 2009 totaled USD 38 million (according to RTS). Pharmacy Chain 36.6 operates more than 1000 stores in 29 regions and 90 cities in Russia.

OAO Veropharm, the company's generics subsidiary, is one of Russia's top five pharmaceutical manufacturers (according to Pharmexpert research). Veropharm's shares are traded in the "B" list on the RTS (ticker: VRPH) and off-list on MICEX (ticker: VRFM). OAO Veropharm's market capitalization as April 24, 2009 was USD 180 million (according to RTS).

ZAO Apteki 36.6 is one of the founding members of the Russian Association of Pharmacy Chains (RAPC).

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION AND IS NOT AN OFFER TO SELL OR AN INVITATION TO MAKE OFFERS TO PURCHASE ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document should not be considered a public offering of securities in the United States. Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933 as amended (the "Securities Act") and may not be offered or sold in the United States or to US persons.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom and (b) persons in the United Kingdom who have (i) professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (the "Order") or (ii) high net worth companies and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49(2) of the Order (all such persons specified in clauses (a) and (b) and together being referred to as "relevant persons"). Any securities referred to in this press release and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.